MX2009012600A - Farmaceutico que contiene el agonista ppar alfa. - Google Patents
Farmaceutico que contiene el agonista ppar alfa.Info
- Publication number
- MX2009012600A MX2009012600A MX2009012600A MX2009012600A MX2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A MX 2009012600 A MX2009012600 A MX 2009012600A
- Authority
- MX
- Mexico
- Prior art keywords
- epithelial cells
- meibomian gland
- isopropyl
- agent
- pparî
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Se pretende proveer un agente para la promoción del crecimiento de las células epiteliales de la glándula meibomiana y células epiteliales de la córnea, y un agente terapéutico para enfermedades de los ojos tales como la disfunción de la glándula meibomiana y ojos secos. Una preparación que contiene un ingrediente activo, [3-[2-[4-(4isopropil-2-(4-triflluorometil)feni l-5-tiazolil]etil]-5-metil-l,2-bencisoxazol-5-il]oxi-acetato, [4-[3-[2-(4-trifluorometil)fenil-4-isopropil-5-tiazolil]propionil ]2-metilfenoxi]acetato o [4-[3-[2-(2-hidroxi-4-clorofenil)-5-isopr opil-4-oxazolill]propionil]-2-metilfenoxi]acetato o una de sus sales farmacológicamente aceptables se utiliza como el agente para promover el crecimiento de las células epiteliales de la glándula meibomiana o células epiteliales de la córnea y el agente terapéutico para enfermedades de los ojos tal como disfunción de la glándula meibomiana y ojos secos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007134183 | 2007-05-21 | ||
PCT/JP2008/059236 WO2008143254A1 (ja) | 2007-05-21 | 2008-05-20 | PPARδアゴニスト含有医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012600A true MX2009012600A (es) | 2010-03-15 |
Family
ID=40031950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012600A MX2009012600A (es) | 2007-05-21 | 2008-05-20 | Farmaceutico que contiene el agonista ppar alfa. |
Country Status (14)
Country | Link |
---|---|
US (2) | US8802705B2 (es) |
EP (1) | EP2151438B1 (es) |
JP (1) | JP5247686B2 (es) |
KR (1) | KR101508020B1 (es) |
CN (1) | CN101801941B (es) |
BR (1) | BRPI0811612A2 (es) |
CA (1) | CA2687957C (es) |
DK (1) | DK2151438T3 (es) |
ES (1) | ES2393424T3 (es) |
MX (1) | MX2009012600A (es) |
PL (1) | PL2151438T3 (es) |
PT (1) | PT2151438E (es) |
RU (1) | RU2449789C2 (es) |
WO (1) | WO2008143254A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7981146B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US7981147B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US7976573B2 (en) | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8007524B2 (en) | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
WO2008027069A1 (en) | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
USD638128S1 (en) | 2009-10-06 | 2011-05-17 | Tearscience, Inc. | Ocular device design |
US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
EP2952189B1 (en) * | 2013-01-31 | 2019-09-18 | Senju Pharmaceutical Co., Ltd. | Clear aqueous solution |
CA2899292A1 (en) * | 2013-01-31 | 2014-08-07 | Senju Pharmaceutical Co., Ltd. | Stable aqueous solution |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
EP3744391B1 (en) | 2013-04-30 | 2023-03-01 | Alcon Inc. | Systems for the treatment of eye conditions |
JPWO2016199871A1 (ja) * | 2015-06-09 | 2018-03-29 | 千寿製薬株式会社 | 神経麻痺性角膜症の治療薬 |
JPWO2017195875A1 (ja) * | 2016-05-12 | 2019-03-22 | 日本ケミファ株式会社 | 創傷治療剤 |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
CN110229886A (zh) * | 2019-07-05 | 2019-09-13 | 杭州笙源生物科技有限公司 | 一种PPARγ用于诊断肝衰竭的新用途及试剂盒及试剂盒用于诊断肝衰竭的应用 |
CN112569179B (zh) * | 2020-12-25 | 2022-12-27 | 上海交通大学医学院附属第九人民医院 | 一种可注射水凝胶体系及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
US5688765A (en) | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
JP4171529B2 (ja) | 1995-06-26 | 2008-10-22 | 大正製薬株式会社 | 点眼剤の充填容器 |
DE69726182T2 (de) | 1996-12-11 | 2004-08-12 | Dana-Farber Cancer Institute, Inc., Boston | Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor |
JP2001039976A (ja) | 1999-05-24 | 2001-02-13 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩 |
TWI284533B (en) | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
WO2002013812A1 (en) * | 2000-08-17 | 2002-02-21 | Pershadsingh Harrihar A | Methods for treating inflammatory diseases |
GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
WO2002069994A2 (en) | 2001-03-07 | 2002-09-12 | Novo Nordisk A/S | Combined use of derivatives of glp-1 analogs and ppar ligands |
AU2002303156A1 (en) * | 2001-03-23 | 2002-10-08 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for ppar |
ATE526319T1 (de) | 2001-08-10 | 2011-10-15 | Nippon Chemiphar Co | Aktivator für den peroxisome proliferator- responsiven rezeptor delta |
IL161351A0 (en) * | 2001-10-12 | 2004-09-27 | Nippon Chemiphar Co | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta |
AU2003248070A1 (en) | 2002-07-16 | 2004-02-02 | Hanshin Yoki Co., Ltd. | Chemical container and method of manufacturing the container |
JP2004175749A (ja) * | 2002-11-28 | 2004-06-24 | Senju Pharmaceut Co Ltd | ドライアイおよびドライアイを伴う疾病の治療剤 |
JP2005008570A (ja) | 2003-06-19 | 2005-01-13 | Santen Pharmaceut Co Ltd | 角膜疾患治療剤 |
ES2357801T3 (es) * | 2003-10-24 | 2011-04-29 | Santen Pharmaceutical Co., Ltd. | Agente terapéutico para trastorno queratoconjuntival. |
JP2006176499A (ja) * | 2004-11-25 | 2006-07-06 | Nippon Seibutsu Seizai:Kk | 眼疾患治療剤 |
US20070027184A1 (en) * | 2005-07-29 | 2007-02-01 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
CN101336113B (zh) * | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | 包括ppar激动剂的药物 |
-
2008
- 2008-05-20 ES ES08764395T patent/ES2393424T3/es active Active
- 2008-05-20 PT PT08764395T patent/PT2151438E/pt unknown
- 2008-05-20 PL PL08764395T patent/PL2151438T3/pl unknown
- 2008-05-20 EP EP08764395A patent/EP2151438B1/en active Active
- 2008-05-20 BR BRPI0811612-1A2A patent/BRPI0811612A2/pt not_active IP Right Cessation
- 2008-05-20 RU RU2009147260/15A patent/RU2449789C2/ru active
- 2008-05-20 CN CN200880025498XA patent/CN101801941B/zh not_active Expired - Fee Related
- 2008-05-20 KR KR1020097026251A patent/KR101508020B1/ko active IP Right Grant
- 2008-05-20 US US12/451,564 patent/US8802705B2/en not_active Expired - Fee Related
- 2008-05-20 WO PCT/JP2008/059236 patent/WO2008143254A1/ja active Application Filing
- 2008-05-20 MX MX2009012600A patent/MX2009012600A/es active IP Right Grant
- 2008-05-20 CA CA2687957A patent/CA2687957C/en not_active Expired - Fee Related
- 2008-05-20 JP JP2009515245A patent/JP5247686B2/ja active Active
- 2008-05-20 DK DK08764395.3T patent/DK2151438T3/da active
-
2014
- 2014-06-27 US US14/317,145 patent/US9463185B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2151438B1 (en) | 2012-10-31 |
RU2009147260A (ru) | 2011-06-27 |
EP2151438A4 (en) | 2010-09-08 |
KR20100037038A (ko) | 2010-04-08 |
PL2151438T3 (pl) | 2013-03-29 |
BRPI0811612A2 (pt) | 2014-11-11 |
JP5247686B2 (ja) | 2013-07-24 |
US8802705B2 (en) | 2014-08-12 |
CA2687957A1 (en) | 2008-11-27 |
RU2449789C2 (ru) | 2012-05-10 |
CN101801941A (zh) | 2010-08-11 |
PT2151438E (pt) | 2012-11-15 |
US20120270910A2 (en) | 2012-10-25 |
WO2008143254A1 (ja) | 2008-11-27 |
US20100190833A1 (en) | 2010-07-29 |
KR101508020B1 (ko) | 2015-04-06 |
JPWO2008143254A1 (ja) | 2010-08-12 |
ES2393424T3 (es) | 2012-12-21 |
CN101801941B (zh) | 2012-12-12 |
CA2687957C (en) | 2014-11-25 |
US9463185B2 (en) | 2016-10-11 |
EP2151438A1 (en) | 2010-02-10 |
US20140343109A1 (en) | 2014-11-20 |
DK2151438T3 (da) | 2012-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012600A (es) | Farmaceutico que contiene el agonista ppar alfa. | |
ES2660571T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y su uso farmacéutico | |
RU2492167C2 (ru) | Производные аминотриазола в качестве агонистов alх | |
PE20060315A1 (es) | Compuestos de tiazol como moduladores de ppar | |
NZ724602A (en) | Ror-gamma modulators and uses thereof | |
NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
RU2017139870A (ru) | Новые агонисты npr-b | |
NO20090834L (no) | Anvendelse av azabicykloheksanderivater | |
TW201808289A (zh) | 含阿托平之水性組成物 | |
JP2011516477A5 (es) | ||
WO2010143074A3 (en) | Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor | |
RU2017121370A (ru) | Противогрибковые агенты | |
HK1138277A1 (en) | Prophylactic and/or therapeutic agent for hyperlipemia | |
PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
EP2170857A4 (en) | 3 ', 4', 5-TRIMETHOXYFLAVONE DERIVATIVES AS THE SLEEP SECRETION STIMULATING AGENT, CORRESPONDING METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
CR20210686A (es) | Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
EP4003952A1 (en) | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof | |
BR0203517A (pt) | Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa | |
MX2023001001A (es) | Agonista del ppar-delta cristalino. | |
CN103702995A (zh) | 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式 | |
CN102711758A (zh) | 用于治疗眼睛的疾病和病症的基于5-(1h-吡唑-5-基)噻唑的化合物 | |
BRPI0906248B8 (pt) | composto, composição farmacêutica para inibir a formação de microtúbulos e método para preparar um composto | |
CL2007002020A1 (es) | Sal xinafoato del etil ester de la 1-[[5-(1(s)-aminoetil)-2-[8-metoxi-2-(trifluorometil)-5-quinolil]-4-oxazolil]carbonil]-4(r)-[(ciclopropil-carbonil)amino]-l-prolina; polimorfo cristalino; proceso de preparacion; composicion farmaceutica; y uso para | |
HRP20140348T1 (hr) | Novi sekundarni derivati 8-hidroksikinolin-7-karboksamida | |
NO20080826L (no) | 3-(2-(dimetylamino)metyl(cykloheks-1-yl))fenolmaleat og dets krystallinske former |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |